(PRESS RELEASE) The Innovation Stage hosted the debut of EYEnovate, a compelling content series highlighting groundbreaking technological innovations in the optical field. Featuring 15-minute talks by eight rising leaders in the optical industry, this series showcased the latest breakthroughs in areas such as automation, artificial intelligence, pharmaceuticals, diagnostics, VR/AR and other cutting-edge technologies.
Brian Levy, OD, MSc, CEO of InflammX Therapeutics, was crowned the winner of the first ever EYEnovate Ocular Horizons Award.
Dr. Levy presented “Novel Platform Technology Targeting the Pathological NLRP3 Inflammasome in Retinal /Kidney Disease.” His presentation addressed a novel therapeutic approach for treating retinal diseases with an orally administered tablet capable of treating both eyes simultaneously.
“Winning the EYEnovate Ocular Horizons Award is an incredible honor,” said Brian Levy OD, MSc, the CEO of InflammX Therapeutics. “We competed in a high caliber program of presentations by exceptional companies in the ophthalmic space. We are proud to have been selected to present at the inaugural 2023 EYEnovate program at Vision Expo West. We at InflammX are excited and confident that the recognition generated by this award will help to drive innovation in the ophthalmic field and provide revolutionary care for future generations.”
To learn more about the inaugural EYEnovate program at Vision Expo West, clickhere.